Utama › Mieloma Pelbagai › Oregon
Kajian klinikal Mieloma Pelbagai di Oregon
20 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi di Oregon.
Bandar di Oregon
Teks kajian rasmi (Bahasa Inggeris)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health And Science University, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07258511Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06784167A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Willamette Valley Cancer Institute and Research Center /ID# 278721, Eugene
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Providence Health & Services, Portland
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Oregon Health and Science University /ID# 272282, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06953960A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07637578A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07075185Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Portland
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT07764978Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Oregon Health & Science University, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Jul 2026 · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center /ID# 267088, Eugene
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Providence Cancer Institute Clackamas Clinic, Clackamas
- dan 7 lagi
Mengambil pesertaFasa 3
Semua umur · Semua jantina · Dikemas kini 10 Jun 2026 · NCT05561387Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Associates of Oregon, Eugene
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Apr 2026 · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Mac 2026 · NCT04988555Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Local Institution - 0016, Portland
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 22 Jan 2026 · NCT06357754cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.